Advertisement

FDG PET/CT in the Initial Staging of Differentiated Thyroid Cancer

  • Gülin Uçmak
  • B. Büşra Demirel
Chapter

Abstract

Differentiated thyroid carcinoma (DTC) is the most frequent thyroid neoplasm and has an excellent prognosis with low mortality rate. Despite the good prognosis, distant metastasis at the time of diagnosis is the poorest prognostic factor in patients with DTC. It is important to consider the most efficient combination of treatments in the initial workup of these high-risk patients. If metastasis were found earlier, some patients might subsequently experience a reduction in tumor burden that may ensure therapy success and significant improvement in progression-free survival. F-18 FDG PET/CT has a valuable role in the initial workup of high-risk patients after total thyroidectomy. In the current guidelines, FDG PET/CT is considered as a significant prognostic tool to determine the patients at highest risk for rapid disease progression and a sensitive method to detect surgically resectable disease for the selection of the patients who may benefit from curative surgery and finally a reliable indicator of therapy response. In conclusion, FDG PET/CT may alter the first-choice treatment modality instead prior to radioiodine ablation therapy (RAT) and may provide the decision for surgery or radiation treatment of FDG-positive metastatic foci; it can provide efficiency of adjuvant RAT due to the reduction of tumor burden and also may contribute an improvement of survival.

Keywords

Differentiated thyroid carcinoma F-18 FDG PET/BT High risk Initial staging Distant metastasis Radioiodine therapy 

References

  1. 1.
    Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.  https://doi.org/10.1210/jc.2005-2838.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Smith SA, Hay ID, Goellner JR, Ryan JJ, McConahey WM. Mortality from papillary thyroid carcinoma. A case-control study of 56 lethal cases. Cancer. 1988;62:1381–8.CrossRefGoogle Scholar
  3. 3.
    Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Res. 1991;51:1234–41.PubMedGoogle Scholar
  4. 4.
    Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110:1451–6.  https://doi.org/10.1002/cncr.22956.CrossRefPubMedGoogle Scholar
  5. 5.
    Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598–605.PubMedGoogle Scholar
  6. 6.
    Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab. 1994;79:98–105.PubMedGoogle Scholar
  7. 7.
    Lind P, Kohlfürst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med. 2006;36(3):194–205.  https://doi.org/10.1053/j.Sem.Nucl.Med.2006.03.002.CrossRefPubMedGoogle Scholar
  8. 8.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37:953–9.  https://doi.org/10.1097/RLU.0b013e31825b2057.CrossRefPubMedGoogle Scholar
  9. 9.
    Akkas BE, Demirel BB, Vural GU. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography. Thyroid. 2014;24(2):287–95.  https://doi.org/10.1089/thy.2013.0195.CrossRefPubMedGoogle Scholar
  10. 10.
    Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498–505.  https://doi.org/10.1210/jc.2005-1534.CrossRefPubMedGoogle Scholar
  11. 11.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.  https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Abraham T, Schöder H. Thyroid cancer—indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med. 2011;41:121–38.  https://doi.org/10.1053/j.semnuclmed.2010.10.006.CrossRefPubMedGoogle Scholar
  13. 13.
    Iwano S, Kato K, Ito S, Tsuchiya K, Naganawa S. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer. Ann Nucl Med. 2012;26:207–13.  https://doi.org/10.1007/s12149-011-0559-y.CrossRefPubMedGoogle Scholar
  14. 14.
    Rosenbaum-Krumme SJ, Gorges R, Bockisch A, Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging. 2012;39:1373–80.  https://doi.org/10.1007/s00259-012-2065-4.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee JW, Lee SM, Lee DH, Kim YJ. Clinical utility of 18F-FDG PET/CT concurrent with therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med. 2013;54:1230–6.  https://doi.org/10.2967/jnumed.112.117119.CrossRefPubMedGoogle Scholar
  16. 16.
    Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, et al. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. Clin Nucl Med. 2015;40(2):111–5.  https://doi.org/10.1097/RLU.0000000000000621.CrossRefPubMedGoogle Scholar
  17. 17.
    Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18:159–69.  https://doi.org/10.1677/ERC-10-0233.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Gülin Uçmak
    • 1
  • B. Büşra Demirel
    • 1
  1. 1.Department of Nuclear MedicineUniversity of Health Sciences (SBÜ) Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalAnkaraTurkey

Personalised recommendations